| 219.66 Delayed Data As of Sep 20 |  +4.55 / +2.12%Today’s Change | 136.44 Today|||52-Week Range 228.19 | +43.41% Year-to-Date |
| Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil Sep 20 / Zacks.com - Paid Partner Content | Edwards Lifesciences Hits a 52-Week High on Solid Prospects Sep 09 / Zacks.com - Paid Partner Content |
| What Makes Edwards Lifesciences (EW) a New Buy Stock Sep 20 / Zacks.com - Paid Partner Content | Here's Why You Should Invest in Edwards Lifesciences (EW) Now Sep 05 / Zacks.com - Paid Partner Content |
| Stock Investors: Do You Need a Late Cycle Plan? Sep 19 / Zacks.com - Paid Partner Content |
| Previous close | 215.11 |
| Today’s open | 216.35 |
| Day’s range | 215.98 - 220.00 |
| Volume | 1,993,520 |
| Average volume (3 months) | 1,198,251 |
| Market cap | $45.7B |
| Earnings growth (last year) | +24.55% |
| Earnings growth (this year) | +13.71% |
| Earnings growth (next 5 years) | +11.67% |
| Revenue growth (last year) | +8.37% |
| P/E ratio | 64.2 |
| Price/Sales | 8.79 |
| Price/Book | 14.52 |
| Today’s change | Today’s % change | |
|---|---|---|
| ISRGIntuitive Surgical | +1.71 | +0.32% |
| SNNSmith & Nephew PLC | -0.03 | -0.06% |
| STESteris plc | +0.87 | +0.60% |
| SYKStryker Corp | +0.15 | +0.07% |
| Next reporting date | October 24, 2019 |
| EPS forecast (this quarter) | $1.22 |
| Annual revenue (last year) | $3.7B |
| Annual profit (last year) | $722.2M |
| Net profit margin | 19.40% |
Sector Health Technology |
Industry Medical Specialties |
Chairman & Chief Executive Officer Michael A. Mussallem |
Chief Financial Officer & Vice President Scott B. Ullem |
Corporate headquarters Irvine, California |
